BridgeBio Oncology grants Cobo stock options, RSUs

BridgeBio Oncology’s principal accounting officer received new option and RSU awards, with a small share withholding to cover tax obligations.

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. (BBOT) reported that Principal Accounting Officer Marc Cobo received equity awards on September 10, 2026. He was granted options to buy 43,700 shares of common stock at $5.52 per share and 9,038 restricted stock units, while 203 shares were withheld to cover taxes on vesting.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Cobo Marc

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F3	43,700	$0.00	$0.00
Grant/Award	Common Stock F1	9,038	$0.00	$0.00
Tax Withholding	Common Stock F2	203	$5.52	$1K

Holdings After Transaction: Stock Option (Right to Buy) — 43,700 contracts (Direct); Common Stock — 14,141 shares (Direct)

Footnotes (3)

1. F1. Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from April 21, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting.
2. F2. Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of RSUs.
3. F3. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 21, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Key Figures

Stock options granted: 43,700 shares Option exercise price: $5.52 per share Option expiration: September 9, 2036 +4 more

7 metrics

Stock options granted 43,700 shares Options to purchase common stock granted to Marc Cobo on September 10, 2026

Option exercise price $5.52 per share Exercise price for 43,700 options granted to Marc Cobo

Option expiration September 9, 2036 Expiration date of the 43,700 stock options

Restricted stock units granted 9,038 RSUs Grant of restricted stock units to Marc Cobo on September 10, 2026

RSU vesting schedule 16 quarterly installments over 4 years RSUs vest from April 21, 2026, subject to continuous service

Monthly option vesting fraction 1/48 per month Portion of options vesting monthly from April 21, 2026

Shares withheld for taxes 203 shares Common shares withheld to satisfy tax obligations on RSU vesting at $5.52 per share

Key Terms

restricted stock units, tax withholding obligations, continuous service

3 terms

restricted stock units financial

"Represents a grant of restricted stock units ("RSUs"), each representing a contingent right"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations"

continuous service financial

"subject to the Reporting Person's continuous service to the Issuer on each such date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did BBOT grant to Principal Accounting Officer Marc Cobo?

Marc Cobo received options for 43,700 shares of common stock at an exercise price of $5.52 per share and a grant of 9,038 restricted stock units on September 10, 2026, as part of his compensation package.

How do the 9,038 RSUs granted by BBOT to Marc Cobo vest?

The 9,038 RSUs vest in 16 equal quarterly installments over four years starting from April 21, 2026, contingent on Marc Cobo’s continuous service. Each vested unit will be settled in one share of BridgeBio Oncology Therapeutics common stock.

What are the key terms of Marc Cobo’s new BBOT stock options?

Marc Cobo was granted options for 43,700 shares with an exercise price of $5.52 per share. 1/48 of the shares vest and become exercisable in substantially equal monthly installments from April 21, 2026, and the options expire on September 9, 2036.

Why did BBOT withhold 203 shares from Marc Cobo on September 10, 2026?

BridgeBio Oncology Therapeutics withheld 203 shares of common stock at $5.52 per share to satisfy Marc Cobo’s tax withholding obligations arising from the vesting of restricted stock units, which is reported as a disposition of shares.

Were Marc Cobo’s BBOT transactions made under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported for these transactions. The awards and the tax-related share withholding are therefore not identified as being executed under a pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 04:24 PM Accepted by SEC EDGAR 09/14/2026 - 04:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cobo Marc

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		A		9,038(1)	A	$0	14,344	D
Common Stock	09/10/2026		F		203(2)	D	$5.52	14,141	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.52	09/10/2026		A		43,700		(3)	09/09/2036	Common Stock	43,700	$0	43,700	D

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from April 21, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting.

2. Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of RSUs.

3. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 21, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

	/s/ Aaron Chan, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)